echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > National medical insurance negotiations officially launched, a number of tumors, rare disease new drugs and other blockbuster products participated in the "soul bargaining"

    National medical insurance negotiations officially launched, a number of tumors, rare disease new drugs and other blockbuster products participated in the "soul bargaining"

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On January 5, on-site negotiations for the adjustment of the national medical insurance drug list officially began
    The industry said that as more and more blockbuster innovative products are expected to enter the medical insurance catalog through negotiation, this is a great boon
    for the majority of patients.
    The National Health Insurance Administration previously announced the "List of Declared Drugs Approved for Formal Review for the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022", with a total of 343 drugs officially passing the formal review
    Including 198 Western medicines and proprietary Chinese medicines outside the list, and 145 Western medicines and proprietary Chinese medicines in the catalog
    In terms of pass rate, the proportion of drugs outside the list was 60%, and the proportion of drugs in the list was 91%.

    It is worth mentioning that the blockbuster innovative products participating in the "soul bargaining" include the PD-1/CTLA-4 bispecific antibody cardunilimab injection independently developed by Akeso, the PD-1 serplulimab approved by Henlius in March 2022, the PD-L1 inhibitor Envolimab injection approved by Corning Jerry/Sidi/Simcere Pharmaceutical in November 2021, the CAR-T relmacel injection with millions of yuan per injection, and Hengrui Pharmaceutical's carrelizumab and Henri Pharmaceutical's carrelizumab injection.
    BeiGene's tislelizumab, Innovent Cindilimab injection, Junshi Biologics teripulimab and other domestic PD-1 monoclonal antibody indications, in addition to a number of high-value rare disease drugs

    Among them, Akeso's PD-1/CTLA4 bispecific antibody Cardunili participated in medical insurance negotiations
    for the first time.
    As an immuno-tumor dual antibody, the drug was approved in June 2022, and its marketing meets the needs of second- and third-line targeted therapy for cervical cancer, and opens a new stage
    of independent commercialization of Akeso.
    It is reported that the current price of the drug is 13220 yuan / 125 mg / bottle, in addition to actively preparing for this medical insurance negotiation, according to Akeso, "Akeso Bio is actively participating in various national and local medical security systems, and adopting patient rescue programs, the annual treatment cost is not higher than 198,000 yuan
    " ”
    WuXi Therapeutics' anticancer drug CD19 CAR-T relmacel injection (Cignora) is also the first time to participate in medical insurance negotiations, and it is worth paying attention to
    whether it can enter medical insurance.
    It is reported that relmacel injection (Cignoda) is priced at 1.
    29 million yuan per vial, and the drug has been approved for two indications, namely the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after two or more lines of systemic therapy and the treatment of refractory or relapsed follicular lymphoma (r/rFL)
    within 24 months after two or more lines of systemic therapy.
    This participation in the negotiation is the first indication.

    In addition, compared with previous rounds of catalog adjustment, this adjustment is appropriately tilted
    towards special groups such as rare diseases and children.
    According to research reports, among the drugs that passed the preliminary review, there are a total of 19 rare disease drugs, including stuximab introduced by BeiGene from EUSA Pharma, Roche's spinal muscular atrophy (SMA) oral drug rispram oral solution powder, Sanofi for the treatment of Fabry's disease injection agalose β

    As more and more blockbuster innovative products are expected to enter the medical insurance catalog through negotiation, this is a great boon
    for the majority of patients.
    Some insiders said that in the past two years, innovative drugs have been approved for clinical application, and drugs have soon been included in the medical insurance catalogue after they are listed, which also means that the entry threshold for medical insurance negotiations has been relaxed for innovative drugs, and medical insurance is willing to give innovative drugs more access opportunities and focus on unmet clinical needs

    For price adjustment, a number of securities research reports believe that the price adjustment of innovative drugs should be relatively moderate in the overall negotiation of the medical insurance catalog, and give greater support to "promoting innovation" on the basis of 'basic protection', on this basis, large pharmaceutical companies with large innovation value, excellent clinical effects and cost advantages are expected to gain advantages in fierce negotiations and fully share the dividends
    of the medical insurance fund.
    According to the data, from 2018 to 2021, the average price of drugs negotiated by medical insurance will decrease by about 50%-60%.

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    Keyword: The national medical insurance negotiations were officially launched, and a number of heavy products such as tumors and new drugs for rare diseases participated in the "soul bargaining" and national medical insurance negotiations
    • Next:Industry: New medical infrastructure is in full swing, and 2023 will still be the peak of medical device procurement
    • Previous:The market space of the drug molecular block industry is broad, and domestic pharmaceutical companies have begun to enter one after another
    [ News Search ] [ Add to favorites ] [ Tell a friend ] [ Print this article ] [ Close Window ]
    Similar information

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.